Pipeline

SNS-101 is designed to block the VISTA checkpoint selectively only within the low pH of the tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. By binding only in the low-pH tumor microenvironment, SNS-101 solves two problems simultaneously: it disarms the checkpoint where it is needed, and it avoids the antibody from binding with noncancerous cells in the bloodstream and triggering an unwanted inflammatory reaction (i.e., cytokine release syndrome). IND-enabling studies are underway to evaluate the potential of SNS-101 as a novel treatment for solid cancers, as both a monotherapy and in combination, that overcomes on-target/off-tumor toxicities seen today with other I/O approaches.

Sensei’s SNS-102 is a monoclonal antibody targeting VSIG4, a B7-family related protein that is often overexpressed on macrophages within the tumor microenvironment and is a potent inhibitor of T cell activity. VSIG4 is also expressed on non-malignant tissues, making it an ideal target for a TMAb antibody. We believe that a tumor-selective blocking monoclonal antibody will have potent anti-tumor immune effects without on-target, off-tumor effects. Sensei anticipates selecting a product candidate for this program in 2023.

Sensei’s SNS-103 is a monoclonal antibody targeting CD39, the upstream, rate-limiting enzyme leading to the breakdown of extracellular ATP. Extracellular ATP represents a potent immunologic “danger signal” which drives immune activation. The ultimate downstream product of this pathway, adenosine, has potent immunosuppressive activity through binding to adenosine receptors. Upregulation of CD39 by tumors is common and leads to a diminished anti-tumor immune response. Sensei’s TMAb platform is the ideal approach for CD39, as the target is also expressed in non-malignant tissues and requires a tumor-selective antibody.